Skip to main
CYRX

CryoPort (CYRX) Stock Forecast & Price Target

CryoPort (CYRX) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 56%
Buy 33%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

CryoPort Inc. reported a total revenue of $44 million in its recent financial performance, reflecting a 15% year-over-year growth on a constant currency basis, indicating a slight increase from the previous quarter's 14% growth. The continuing rise in gene therapy programs, particularly in oncology and rare diseases, suggests a robust increase in demand for CryoPort's integrated temperature-controlled supply chain solutions as the market embraces these therapies. Additionally, the expectation of increased commercial revenue and clinical trial activity aligns with the overall positive market dynamics, further supporting a favorable outlook for CryoPort's stock.

Bears say

CryoPort Inc. is experiencing a slowdown in funding for start-up companies in its sector, with a decline in Series A and seed funding, which may impact future growth. The company's Life Sciences Services revenue growth has decelerated, recording a 16% increase compared to 21% in the previous quarter, and its adjusted EBITDA margin remains negative at (1.5%), below the consensus estimate. Additionally, the bear case scenario anticipates ongoing revenue challenges due to a reduced pace of cell and gene therapy approvals, coupled with a decrease in demand for MVE freezers, ultimately leading to lowered earnings per share projections for 2026.

CryoPort (CYRX) has been analyzed by 9 analysts, with a consensus rating of Buy. 56% of analysts recommend a Strong Buy, 33% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CryoPort and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CryoPort (CYRX) Forecast

Analysts have given CryoPort (CYRX) a Buy based on their latest research and market trends.

According to 9 analysts, CryoPort (CYRX) has a Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CryoPort (CYRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.